Lixisenatide

Inject subcutaneously once a day within the hour prior to the first meal of the day. SOLIQUA 100/33 pen delivers 15 units to 60 units per injection. ( 2.1 , 2.2 ) Maximum daily dosage is 60 units (60 units of insulin glargine and 20 mcg of lixisenatide). Discontinue basal insulin or GLP-1 receptor agonist prior to initiation. In patients naive to basal insulin or to a GLP-1 receptor agonist, currently on less than 30 units of basal insulin, or on a GLP-1 receptor agonist, the recommended starting dosage is 15 units subcutaneously once daily. In patients inadequately controlled on 30 to 60 units of basal insulin, the starting dosage is 30 units subcutaneously once daily. See Full Prescribing Information for titration recommendations. Inject subcutaneously in abdominal area, thigh, or upper arm and rotate injection sites within the same region from one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis. Do not administer intravenously, or via an infusion pump. Do not dilute or mix with any other insulin products or solutions. 2.1 Important Dosage Information SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide.